Sign in
Taking people in FrancePhase 4

Immune Effects of Clozapine in Parkinson's Disease Patients

Checks antibody and immune cell levels in Parkinson's patients taking clozapine for psychosis.

Key facts

Who runs it
Centre Hospitalier Universitaire, Amiens
Where
Salouël, FranceSee the site
Trial code
Registry title
Clozapine-related Immunodeficiency in Parkinsons Disease
Status
Recruiting
Phase
Phase 4
People taking part
24 people, planned
Started
1 Oct 2024
Expected to end
Sept 2027
Type of study
Interventional
Treatments tested
  • blood test
Record updated
19 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Parkinson's disease who have psychotic symptoms and need clozapine. It checks immune blood levels at 6 months and 1 year.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Parkinson's disease (MDS 2015 criteria) with psychotic symptoms that need clozapine treatment.
Earlier treatment
No immune-suppressing or immune-modulating treatment, anti-epileptic treatment or chemotherapy now or stopped less than 5 years ago. No long-term corticosteroids and no history of radiotherapy.
Biomarker or test result
Normal white blood cell count at the start: at least 3500/mm3 white blood cells and at least 2000/mm3 neutrophils.

Main reasons for not taking part

  • Cannot use clozapine because of a contraindication or allergy
  • Cannot have regular blood tests
  • Another cause of weak immunity, including HIV infection or cancer treated less than 5 years ago
  • MoCA score of 23 or less (major thinking problems)
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • Patient ≥ 18 years old with Parkinson's disease according to MDS 2015 criteria
  • Psychotic symptoms requiring treatment with Clozapine
  • Patients with initially a normal leukocyte count (number of white blood cells; ≥ 3500/mm3 [3.5 x 109/l] and an absolute neutrophil count PNN ≥ 2000/mm3 [2 x 109/l])
  • patients in whom the number of white blood cells (WBC) and the absolute number of neutrophils (PNN) may be determined regularly at the following intervals: once a week during the first 18 weeks of treatment and, thereafter, at least every 4 weeks for the duration of the treatment. This monitoring must be continued throughout the treatment and for 4 weeks who follow the complete cessation of CLOZAPINE
  • Informed and written consent
  • Affiliation to a social security system

Who cannot take part

  • History of granulopenia or toxic or idiosyncratic agranulocytosis (unless it results from previous chemotherapy)
  • Treatment with CLOZAPINE should not be started at the same time as substances known to have a high potential for inducing agranulocytosis; The concomitant administration of depot antipsychotics is not recommended
  • Alcoholic or induced psychosis, drug intoxication, comatose states
  • Chemotherapy active or stopped for less than 5 years
  • Long-term use of corticosteroids
  • Hypersensitivity to the active substance or to any of the excipients
  • History of agranulocytosis induced by CLOZAPINE
  • Functional bone marrow failure
  • Uncontrolled epilepsy
  • Severe renal or cardiac disorders (eg: myocarditis)
  • Active liver disease with nausea, anorexia or jaundice; progressive liver disease, liver failure
  • Solid or hematologic cancer active or treated for less than 5 years
  • Human immunodeficiency virus infection
  • Nephrotic syndrome
  • A history of radiotherapy
  • Patient with potentially major cognitive disorders defined by a MoCA score less than or equal to 23
  • Patients with a contraindication to the use of Clozapine according to the summary of product characteristics (SPC)
  • Patients who cannot receive regular blood tests
  • Circulatory collapse and / or CNS depression regardless of the aetiology
  • Paralytic ileus
  • Patient with another potential cause of immunosuppression
  • Immunosuppressive or immune modulatory treatment active or stopped for less than 5 years
  • Anti-epileptic treatment active or stopped for less than 5 years
  • Already known constitutional immune deficiency
  • Protein-losing enteropathy
  • Pregnant or breastfeeding women
  • Patient under guardianship/curatorship or deprived of liberty

Where in France

  • CHU Amiens-PicardieSalouël, FranceContact: Mickaël AUBIGNAT, MDTaking people

About the trial

What the trial wants to find out

Clozapine is a second generation antipsychotic drug used in psychiatry to treat schizophrenia, affective disorders or certain symptoms of dementia. In neurology, clozapine is frequently used and recommended to manage symptoms of psychosis associated with Parkinson's disease (PD). The risk of neutropenia or agranulocytosis associated with clozapine estimated at 1.3% is well known to doctors around the world with a peak at one month and a decrease in risk after more than a year of treatment. This risk has led to the policy of "no blood, no drugs" and monitoring of the complete blood count (CBC) weekly for 18 weeks and then monthly for the duration of treatment.

Read full original descriptionShow less

Some studies suggest an increased risk of infections related to immunodeficiency induced by clozapine itself. This clozapine-induced immunodeficiency would be comparable to that encountered in patients with common variable immunodeficiency or under immunosuppressive treatment. In addition, this immunosuppressive effect linked to clozapine would not be dose dependent but time dependent. However, the only studies currently performed have been in psychiatric patients treated for schizophrenia.

It seems important to specifically explore clozapine-related immunodeficiency in PD patients treated with clozapine for PD-related psychosis. In this study, the investigators propose to evaluate the variations in serum immunoglobulin levels and lymphocyte subpopulations (B, T, NK) in parkinsonian patients treated with Clozapine at 6 months and 1 year after initiation of treatment.

Treatments tested

  • blood test

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of Clozapine-related Immunodeficiency Effect in Parkinsons Disease Patients
Plain-language title
Immune Effects of Clozapine in Parkinson's Disease PatientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 November 2025